Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated patients achieve disease stabilisation or better at the first radiological evaluation. In add...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Sci Rep
Главные авторы: Giampieri, Riccardo, Prete, Michela del, Prochilo, Tiziana, Puzzoni, Marco, Pusceddu, Valeria, Pani, Fabiana, Maccaroni, Elena, Mascia, Roberta, Baleani, Maria Giuditta, Meletani, Tania, Berardi, Rossana, Lanzillo, Anna Maria, Mariotti, Stefano, Zaniboni, Alberto, Cascinu, Stefano, Scartozzi, Mario
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380985/
https://ncbi.nlm.nih.gov/pubmed/28378839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep45703
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы